Tumour-induced IL-6 is considered an essential player in cancer-associated metabolic alterations,42 and IL-6 is able to induce muscle and fat wasting in mice.43,44 Interestingly, IL-6 alters AA turnover; it reduces the arterial AA concentrations albeit the net muscle protein breakdown is increased.45 This suggests that the IL-6 could increase the demand of glutamine in CRC patients with systemic inflammation. The gene discussed is IL6; the disease is neoplasm.